A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy

Genetic factors contribute to more than 40% of prostate cancer risk, and mutations in BRCA1 and BRCA2 are well-established risk factors. By using target capture-based deep sequencing to identify potential pathogenic germline mutations, followed by Sanger sequencing to determine the loci of the mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiuli, Tong, Dali, Liu, Gaolei, Yi, Yuting, Xu, Jing, Yang, Xingxia, Wang, Linang, Zhang, Jun, Ye, Jin, Zhang, Yao, Yuan, Gang, Wang, Peng, Chen, Rongrong, Guan, Yanfang, Yi, Xin, Zhang, Dianzheng, Jiang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Bedside to Bench Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067857/
https://www.ncbi.nlm.nih.gov/pubmed/29580149
http://dx.doi.org/10.1080/15384047.2018.1451278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067857/
https://www.ncbi.nlm.nih.gov/pubmed/29580149
http://dx.doi.org/10.1080/15384047.2018.1451278

Ejemplares similares